background
banner

DERMOFUCIN 2% Price

Active Substance: Fusidic acid (as sodium salt).

9
UAD , based on 7541 reviews.
View Drug details

Overview

Welcome to Dwaey, specifically on DERMOFUCIN 2% Ointment page.
This medicine contains an important and useful components, as it consists of Fusidic acid (as sodium salt).
DERMOFUCIN 2% is available in the market in concentration 20mg/g and in the form of Ointment.

AMMAN PHARMACEUTICAL INDUSTRIES CO. LTD. is the producer of DERMOFUCIN 2% and it is imported from JORDAN, The most popular alternatives of DERMOFUCIN 2% are listed downward .

Mode Of Action

Fusidic acid disrupts translocation of peptide subunits and elongating the peptide chain of susceptible bacteria, thus inhibiting protein synthesis.

Indication

  • Fusidate Ointment is indicated for treatment of skin infections caused by Staphylococci
  • Streptococci
  • Corynebacterium minutissimum and other Fusidate sensitive organisms. The most important indications being: impetigo
  • boils
  • abscess
  • varicose ulcers
  • skin grafts
  • hidradenitis
  • infected wounds
  • sycosis barbae
  • paronychia
  • folliculitis
  • carbuncles and erythrasma.

Precaution

Prolonged treatment should be avoided. Liver impairment. Pregnancy. Caution should be observed when applying Fusidate Ointment near the eye region as this preparation may cause irritation if it gets into the eye.

Side Effects

  • Fusidate Ointment is remarkably well tolerated
  • and there is an extremely low frequency of hypersensitivity reactions. Rashes and irritation.

Contra indication

Known hypersensitivity to Fusidic acid, severe hepatic failure.

Pregnancy and lactation

Interaction

Synergistic action with antistaphylococcal penicillin. Antagonism with ciprofloxacin.

Alternatives Price List

  • UCIDERM 2%UAD 11
  • FUTASOLE 2%UAD 11
  • FUSIVER 2%UAD 9
  • FUSIBACT 2%UAD 11
  • FUCIDIN 500mgUAD 47

Releated Products

banner

Report Price Error

Please feel welcome to contact Us with any price or medical error. Our doctors will receive any reports.